523 related articles for article (PubMed ID: 32265714)
1. The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents.
Zhou J; Kang Y; Chen L; Wang H; Liu J; Zeng S; Yu L
Front Pharmacol; 2020; 11():343. PubMed ID: 32265714
[TBL] [Abstract][Full Text] [Related]
2. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
[TBL] [Abstract][Full Text] [Related]
3. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells.
Rietbroek RC; van de Vaart PJ; Haveman J; Blommaert FA; Geerdink A; Bakker PJ; Veenhof CH
J Cancer Res Clin Oncol; 1997; 123(1):6-12. PubMed ID: 8996534
[TBL] [Abstract][Full Text] [Related]
4. Organic cation transporters are determinants of oxaliplatin cytotoxicity.
Zhang S; Lovejoy KS; Shima JE; Lagpacan LL; Shu Y; Lapuk A; Chen Y; Komori T; Gray JW; Chen X; Lippard SJ; Giacomini KM
Cancer Res; 2006 Sep; 66(17):8847-57. PubMed ID: 16951202
[TBL] [Abstract][Full Text] [Related]
5. Molecular aspects of resistance to antitumor platinum drugs.
Brabec V; Kasparkova J
Drug Resist Updat; 2002; 5(3-4):147-61. PubMed ID: 12237082
[TBL] [Abstract][Full Text] [Related]
6. [Current status of and future perspectives for platinum antitumor drugs].
Chikuma M; Sato T; Komeda S
Yakugaku Zasshi; 2008 Mar; 128(3):307-16. PubMed ID: 18311048
[TBL] [Abstract][Full Text] [Related]
7. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
8. New platinum antitumor complexes.
Kelland LR
Crit Rev Oncol Hematol; 1993 Dec; 15(3):191-219. PubMed ID: 8142057
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin and platinum drugs at the molecular level. (Review).
Boulikas T; Vougiouka M
Oncol Rep; 2003; 10(6):1663-82. PubMed ID: 14534679
[TBL] [Abstract][Full Text] [Related]
10. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin.
Liedert B; Materna V; Schadendorf D; Thomale J; Lage H
J Invest Dermatol; 2003 Jul; 121(1):172-6. PubMed ID: 12839578
[TBL] [Abstract][Full Text] [Related]
12. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
To KK; Tong WS; Fu LW
Lung Cancer; 2017 Jan; 103():58-65. PubMed ID: 28024697
[TBL] [Abstract][Full Text] [Related]
13. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
[TBL] [Abstract][Full Text] [Related]
14. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts.
Kasparkova J; Novakova O; Farrell N; Brabec V
Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292
[TBL] [Abstract][Full Text] [Related]
15. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes.
Ahmad S
Chem Biodivers; 2010 Mar; 7(3):543-66. PubMed ID: 20232326
[TBL] [Abstract][Full Text] [Related]
16. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines.
Kitada N; Takara K; Minegaki T; Itoh C; Tsujimoto M; Sakaeda T; Yokoyama T
Cancer Chemother Pharmacol; 2008 Sep; 62(4):577-84. PubMed ID: 18030470
[TBL] [Abstract][Full Text] [Related]
17. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
Mellish KJ; Kelland LR; Harrap KR
Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
[TBL] [Abstract][Full Text] [Related]
18. Status of bi- and multi-nuclear platinum anticancer drug development.
Zhang J; Wang L; Xing Z; Liu D; Sun J; Li X; Zhang Y
Anticancer Agents Med Chem; 2010 May; 10(4):272-82. PubMed ID: 20184553
[TBL] [Abstract][Full Text] [Related]
19. Nonclassical platinum antitumor agents: perspectives for design and development of new drugs complementary to cisplatin.
Farrell N
Cancer Invest; 1993; 11(5):578-89. PubMed ID: 8402226
[TBL] [Abstract][Full Text] [Related]
20. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells.
Materna V; Liedert B; Thomale J; Lage H
Int J Cancer; 2005 Jun; 115(3):393-402. PubMed ID: 15688364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
